TRIM21 and neoplasm: For the antibody myositis spectrum in patients after tumor treatment, the positive rate reached 72.73%, and we compared patients with interstitial pneumonia anti-RO-52 antibody positive after tumor treatment and patients with untreated interstitial pneumonia, compared with the average lung time from symptom onset to diagnosis.